alere selling 25% of bbi, page-52

No idea Kiddo - I am just speculating on possible scenarios.

If royalties to a component supplier were going to be as high as 10-20% I thought perhaps issuing shares to Anteo in the new company may have been an option?

All I know is that the Quarterly Report was a gem IMO

Happy to hear others thoughts and views?

The below statement is why Ante's IP Mixngo values the company many times higher then where it currently is - This has nothing to do with deals but understanding the market and what the below statement means :

"Sensitivities we achieved on the lateral flow tests
rivalled those that are achieved, for the antibodies tested, in laboratory-based test"